Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Mar;70(3):1246-1247.
doi: 10.1007/s10620-025-08855-w. Epub 2025 Jan 22.

Delays in Initiating Biologic Therapy in Patients with Inflammatory Bowel Disease-Perception and Reality

Anish J Kuriakose Kuzhiyanjal  1 , Sreedhar Subramanian  2 , Jimmy K Limdi  3   4
Affiliations

Delays in Initiating Biologic Therapy in Patients with Inflammatory Bowel Disease-Perception and Reality

Anish J Kuriakose Kuzhiyanjal et al. Dig Dis Sci. 2025 Mar.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Declarations. Conflict of interest: Anish Kuzhiyanjal has received chairing fees from Dr. Falk Pharma. Sreedhar Subramanian has received speaker fees from MSD, Actavis, AbbVie, Dr. Falk Pharma, Ipsen, and Shire; received educational grants from MSD, AbbVie, and Actavis; and served on the advisory board for AbbVie, Dr. Falk Pharma, and Vifor Pharma. Jimmy K. Limdi has received speaker or consultancy fees from Abbvie, Arena, Abivax, Alphasigma, Bristol Myers Squibb, Celltrion, Eli Lilly, Janssen, MSD, Pfizer and Takeda and research grants from Galapagos and Takeda. Ethical approval: This was an audit and service evaluation study and as such exempt from ethical approval.

Similar articles

See all similar articles

Cited by

References

    1. Abadir A, Troia A, Said H, Tarugu S, Billingsley BC, Sairam N et al. Factors Associated with Delays in Initiating Biologic Therapy in Patients with Inflammatory Bowel Disease. Dig Dis Sci. 2024;69:2796–2803. - DOI - PubMed
    1. Noor NM, Lee JC, Bond S, Dowling F, Brezina B, Patel KV et al. A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn’s disease (PROFILE): a multicentre, open-label randomised controlled trial. Lancet Gastroenterol Hepatol. 2024;9:415–427. - DOI - PubMed - PMC
    1. Ungaro RC, Aggarwal S, Topaloglu O, Lee WJ, Clark R, Colombel JF. Systematic review and meta-analysis: efficacy and safety of early biologic treatment in adult and paediatric patients with Crohn’s disease. Aliment Pharmacol Ther. 2020;51:831–842. - DOI - PubMed - PMC
    1. Mohan BP, Fatima N, Khan SR, Kassab L, Chandan S, Asokkumar R et al. Early Remission With Induction Therapy Predicts Long-Term Remission in Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis. Am J Gastroenterol. 2023;118:2084–2087. - DOI - PubMed
    1. Quraishi MN, Dobson E, Ainley R, Din S, Wakeman R, Cummings F et al. Establishing key performance indicators for inflammatory bowel disease in the UK. Frontline Gastroenterol. 2023;14:407–414. - DOI - PubMed - PMC

LinkOut - more resources